Sun Pharma Advanced Research Company Limited has informed the Exchange about PDP-716 NDA Update

Regulatory & Legal View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹180.00

prior close

₹178.97

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%+1.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+1.4% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.9

15m

+3.0

30m

+3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+0.6+1.1+0.2+1.4

Next day

+0.0+1.7-1.7+0.7-0.7

+18.3+1.8+16.5+0.5+17.9

+31.0+3.4+27.6+1.7+29.3

+29.0+4.1+24.8+1.9+27.1

+23.7+4.1+19.6+1.9+21.8

+9.6+2.3+7.3+1.2+8.5

15d

+14.4+1.8+12.6-0.6+15.0

+32.1+10.8+21.3+3.8+28.3

+26.8+10.3+16.5+7.8+19.0

+11.3+14.9-3.6+8.2+3.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma Advanced Research Company's licensing partner Ocuvex Therapeutics Inc. has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The CRL was issued because of inspection findings at the finished product manufacturing facility. The FDA has not raised any other concerns with the PDP-716 NDA itself, suggesting the drug candidate may still be viable pending resolution of manufacturing issues.

Likely market impact

This is a setback for PDP-716's approval timeline as manufacturing inspection deficiencies must be addressed before FDA can approve the NDA. The stock may face negative sentiment in the short term.